Business
WNBA's original dynasty rebuilt: Houston Comets face 'mad sprint' to 2027 return
By Jamal Sanders
US FDA approves Inovio’s treatment for rare throat disease; shares surge
Lila Johnson
Lila Johnson
Reporter · Fargo, ND
Lila Johnson is a seasoned business reporter with a background in finance, having graduated from the University of North Dakota. She has previously worked with local business journals and focuses on small business success stories and entrepreneurial initiatives.
More from Lila →Reporter · Friday, October 30, 2026 at 8:44 PM · 1 min read
Oct 30 (Reuters) The US Food and Drug Administration has approved Inovio Pharmaceuticals treatment for a rare respiratory condition, the regulator said on Friday, marking the company s first approved product. Shares of Inovio were up 215% in extending trading. Inovio s therapy INO-3107, branded as Voceryq, gives patients with recurrent respiratory papillomatosis a new treatment option for the condition, which causes growths in the airways and often requires repeated surgeries. (Reporting by Sahil Pandey, Christy Santhosh and Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber)
Up nextWNBA's original dynasty rebuilt: Houston Comets face 'mad sprint' to 2027 returnBusiness · 6 min read
More Business stories
Community
Fitch revises France’s outlook to ‘negative’ on worsening debt dynamics
By Jenna Larson
Arts
Vikings and Lions match up NFL’s stingiest defense vs. high-scoring offense in NFC North showdown
By Erik Svenson
Community
S&P Global revises outlook on Meta to negative on cashflow concerns
By Jenna Larson